BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 30220099)

  • 1. Prolonged inhibition of hepatocellular carcinoma cell proliferation by combinatorial expression of defined transcription factors.
    Takashima Y; Horisawa K; Udono M; Ohkawa Y; Suzuki A
    Cancer Sci; 2018 Nov; 109(11):3543-3553. PubMed ID: 30220099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion of hepatoma cells to hepatocyte-like cells by defined hepatocyte nuclear factors.
    Cheng Z; He Z; Cai Y; Zhang C; Fu G; Li H; Sun W; Liu C; Cui X; Ning B; Xiang D; Zhou T; Li X; Xie W; Wang H; Ding J
    Cell Res; 2019 Feb; 29(2):124-135. PubMed ID: 30560924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HNF1A POU Domain Mutations Found in Japanese Liver Cancer Patients Cause Downregulation of
    Haque E; Teeli AS; Winiarczyk D; Taguchi M; Sakuraba S; Kono H; Leszczyński P; Pierzchała M; Taniguchi H
    Genes (Basel); 2022 Feb; 13(3):. PubMed ID: 35327967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
    Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
    Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HNF1α-regulated lncRNA HNF1A-AS1 reverses the malignancy of hepatocellular carcinoma by enhancing the phosphatase activity of SHP-1.
    Ding CH; Yin C; Chen SJ; Wen LZ; Ding K; Lei SJ; Liu JP; Wang J; Chen KX; Jiang HL; Zhang X; Luo C; Xie WF
    Mol Cancer; 2018 Feb; 17(1):63. PubMed ID: 29466992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive network analysis of the molecular mechanisms associated with sorafenib resistance in hepatocellular carcinoma.
    Lin H; Zhang R; Wu W; Lei L
    Cancer Genet; 2020 Jul; 245():27-34. PubMed ID: 32559715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
    Ni CX; Qi Y; Zhang J; Liu Y; Xu WH; Xu J; Hu HG; Wu QY; Wang Y; Zhang JP
    Oncotarget; 2016 Nov; 7(48):79544-79556. PubMed ID: 27783993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
    Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H
    Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inter-regulation of IGFBP1 and FOXO3a unveils novel mechanism in ursolic acid-inhibited growth of hepatocellular carcinoma cells.
    Yang LJ; Tang Q; Wu J; Chen Y; Zheng F; Dai Z; Hann SS
    J Exp Clin Cancer Res; 2016 Mar; 35():59. PubMed ID: 27036874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DEPDC1 promotes cell proliferation and suppresses sensitivity to chemotherapy in human hepatocellular carcinoma.
    Zhou C; Wang P; Tu M; Huang Y; Xiong F; Wu Y
    Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31189746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting PRMT5 Activity Inhibits the Malignancy of Hepatocellular Carcinoma by Promoting the Transcription of HNF4α.
    Zheng BN; Ding CH; Chen SJ; Zhu K; Shao J; Feng J; Xu WP; Cai LY; Zhu CP; Duan W; Ding J; Zhang X; Luo C; Xie WF
    Theranostics; 2019; 9(9):2606-2617. PubMed ID: 31131056
    [No Abstract]   [Full Text] [Related]  

  • 14. Choline Kinase α Mediates Interactions Between the Epidermal Growth Factor Receptor and Mechanistic Target of Rapamycin Complex 2 in Hepatocellular Carcinoma Cells to Promote Drug Resistance and Xenograft Tumor Progression.
    Lin XM; Hu L; Gu J; Wang RY; Li L; Tang J; Zhang BH; Yan XZ; Zhu YJ; Hu CL; Zhou WP; Li S; Liu JF; Gonzalez FJ; Wu MC; Wang HY; Chen L
    Gastroenterology; 2017 Apr; 152(5):1187-1202. PubMed ID: 28065789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation.
    Zhou X; Zhu A; Gu X; Xie G
    Cell Oncol (Dordr); 2019 Jun; 42(3):369-380. PubMed ID: 30788663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-6809-5p mediates luteolin-induced anticancer effects against hepatoma by targeting flotillin 1.
    Yang PW; Lu ZY; Pan Q; Chen TT; Feng XJ; Wang SM; Pan YC; Zhu MH; Zhang SH
    Phytomedicine; 2019 Apr; 57():18-29. PubMed ID: 30668319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reprograming of Glucose Metabolism by Zerumbone Suppresses Hepatocarcinogenesis.
    Wani NA; Zhang B; Teng KY; Barajas JM; Motiwala T; Hu P; Yu L; Brüschweiler R; Ghoshal K; Jacob ST
    Mol Cancer Res; 2018 Feb; 16(2):256-268. PubMed ID: 29187559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of Hepatocyte Nuclear Factor 4 α by Long-term Infection of Hepatitis B Virus Contributes to Tumor Cell Proliferation.
    Park S; Ha YN; Dezhbord M; Lee AR; Park ES; Park YK; Won J; Kim NY; Choo SY; Shin JJ; Ahn CH; Kim KH
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32023898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.
    Ding J; Wen W; Xiang D; Yin P; Liu Y; Liu C; He G; Cheng Z; Yin J; Sheng C; Zhang W; Nan F; Ye W; Zhang X; Wang H
    Oncotarget; 2015 May; 6(13):11627-39. PubMed ID: 25890498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant adenovirus carrying the hepatocyte nuclear factor-1alpha gene inhibits hepatocellular carcinoma xenograft growth in mice.
    Zeng X; Lin Y; Yin C; Zhang X; Ning BF; Zhang Q; Zhang JP; Qiu L; Qin XR; Chen YX; Xie WF
    Hepatology; 2011 Dec; 54(6):2036-47. PubMed ID: 21898499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.